Cargando…
Bafetinib Suppresses the Transcription of PD-L1 Through c-Myc in Lung Cancer
Given the limitations of the existing antibody-based therapies, including immune-related adverse events, poor response rates, and intravenous route of dosing, small molecules inhibitors targeting PD-L1 are highly desirable. By cell-based screening, we found that tyrosine kinase inhibitor Bafetinib d...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9201485/ https://www.ncbi.nlm.nih.gov/pubmed/35721177 http://dx.doi.org/10.3389/fphar.2022.897747 |